1
|
D'Arpino MC, Sineli PE, Goroso G, Watanabe W, Saavedra ML, Hebert EM, Martínez MA, Migliavacca J, Gerstenfeld S, Chahla RE, Bellomio A, Albarracín VH. Wastewater monitoring of SARS-CoV-2 gene for COVID-19 epidemiological surveillance in Tucumán, Argentina. J Basic Microbiol 2024; 64:e2300773. [PMID: 38712352 DOI: 10.1002/jobm.202300773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 03/12/2024] [Accepted: 04/08/2024] [Indexed: 05/08/2024]
Abstract
Wastewater-based epidemiology provides temporal and spatial information about the health status of a population. The objective of this study was to analyze and report the epidemiological dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the province of Tucumán, Argentina during the second and third waves of coronavirus disease 2019 (COVID-19) between April 2021 and March 2022. The study aimed to quantify SARS-CoV-2 RNA in wastewater, correlating it with clinically reported COVID-19 cases. Wastewater samples (n = 72) were collected from 16 sampling points located in three cities of Tucumán (San Miguel de Tucumán, Yerba Buena y Banda del Río Salí). Detection of viral nucleocapsid markers (N1 gene) was carried out using one-step reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Viral loads were determined for each positive sample using a standard curve. A positive correlation (p < 0.05) was observed between viral load (copies/mL) and the clinically confirmed COVID-19 cases reported at specific sampling points in San Miguel de Tucumán (SP4, SP7, and SP8) in both months, May and June. Indeed, the high viral load concurred with the peaks of COVID-19 cases. This method allowed us to follow the behavior of SARS-CoV-2 infection during epidemic outbreaks. Thus, wastewater monitoring is a valuable epidemiological indicator that enables the anticipation of increases in COVID-19 cases and tracking the progress of the pandemic. SARS-CoV-2 genome-based surveillance should be implemented as a routine practice to prepare for any future surge in infections.
Collapse
Affiliation(s)
- María Cecilia D'Arpino
- Laboratory of Molecular and Ultraestructural Microbiology, Centro Integral de Microscopía Electrónica, (CIME-UNT-CONICET), Facultad de Agronomía, Zootecnia y Veterinaria, Universidad Nacional de Tucumán, Tucumán, Argentina
| | - Pedro Eugenio Sineli
- Planta Piloto de Procesos Industriales Microbiológicos (PROIMI-CONICET), Tucumán, Argentina
| | - Gustavo Goroso
- Laboratorio de Processamento de Sinais e Modelagem de Sistemas Biológicos. Núcleo de Pesquisas Tecnológicas, Universidade Mogi das Cruzes, Sao Paulo, Brasil
| | - William Watanabe
- Laboratorio de Processamento de Sinais e Modelagem de Sistemas Biológicos. Núcleo de Pesquisas Tecnológicas, Universidade Mogi das Cruzes, Sao Paulo, Brasil
| | | | | | | | | | | | | | - Augusto Bellomio
- Instituto Superior de Investigaciones Biológicas (INSIBIO, CONICET-Universidad Nacional de Tucumán), Tucumán, Argentina
| | - Virginia Helena Albarracín
- Laboratory of Molecular and Ultraestructural Microbiology, Centro Integral de Microscopía Electrónica, (CIME-UNT-CONICET), Facultad de Agronomía, Zootecnia y Veterinaria, Universidad Nacional de Tucumán, Tucumán, Argentina
- Facultad de Ciencias Naturales e Instituto Miguel Lillo, Universidad Nacional Tucumán, Tucumán, Argentina
| |
Collapse
|
2
|
Klingler J, Kowdle S, Bandres JC, Emami-Gorizi R, Alvarez RA, Rao PG, Amanat F, Gleason C, Kleiner G, Simon V, Edelstein A, Perandones C, Upadhyay C, Lee B, Hioe CE. Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities. Front Immunol 2024; 15:1382619. [PMID: 38779671 PMCID: PMC11109367 DOI: 10.3389/fimmu.2024.1382619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 04/19/2024] [Indexed: 05/25/2024] Open
Abstract
Introduction Antibodies against the SARS-CoV-2 spike protein are a critical immune determinant for protection against the virus. While virus neutralization is a key function of spike-specific antibodies, antibodies also mediate Fc-dependent activities that can play a role in protection or pathogenesis. Methods This study characterized serum antibody responses elicited after two doses of heterologous adenovirus-vectored (Ad26/ Ad5) vaccines. Results Vaccine-induced antibody binding titers and Fc-mediated functions decreased over six months, while neutralization titers remained stable. Comparison of antibody isotypes elicited after Ad26/Ad5 vs. LNP-mRNA vaccination and after infection showed that anti-spike IgG1 were dominant and produced to high levels in all groups. The Ad26/Ad5 vaccines also induced IgG4 but not IgG2 and IgG3, whereas the LNP-mRNA vaccines elicited a full Ig spectrum (IgM, IgG1-4, IgA1-2). Convalescent COVID-19 patients had mainly IgM and IgA1 alongside IgG1. Despite these differences, the neutralization potencies against early variants were similar. However, both vaccine groups had antibodies with greater Fc potencies of binding complement and Fcg receptors than the COVID-19 group. The Ad26/Ad5 group also displayed a greater potency of RBD-specific antibody-mediated cellular phagocytosis. Discussion Antibodies with distinctive quality were induced by different vaccines and infection. The data imply the utility of different vaccine platforms to elicit antibody responses with fine-tuned Fc activities.
Collapse
Affiliation(s)
- Jéromine Klingler
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- James J. Peters VA Medical Center, Bronx, NY, United States
| | - Shreyas Kowdle
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | | | | | - Raymond A. Alvarez
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Priyanka G. Rao
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Fatima Amanat
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Charles Gleason
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Giulio Kleiner
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Viviana Simon
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Alexis Edelstein
- Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina
| | - Claudia Perandones
- Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) Dr. Carlos G. Malbrán, Buenos Aires, Argentina
| | - Chitra Upadhyay
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Benhur Lee
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Catarina E. Hioe
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- James J. Peters VA Medical Center, Bronx, NY, United States
| |
Collapse
|
3
|
Batmunkh B, Otgonbayar D, Shaarii S, Khaidav N, Shagdarsuren OE, Boldbaatar G, Danzan NE, Dashtseren M, Unurjargal T, Dashtseren I, Dagvasumberel M, Jagdagsuren D, Bayandorj O, Biziya B, Surenjid S, Togoo K, Bat-Erdene A, Narmandakh Z, Choijilsuren G, Batmunkh U, Soodoi C, Boldbaatar EA, Byambatsogt G, Byambaa O, Deleg Z, Enebish G, Chuluunbaatar B, Zulmunkh G, Tsolmon B, Gunchin B, Chimeddorj B, Dambadarjaa D, Sandag T. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia. PLoS One 2023; 18:e0295167. [PMID: 38064430 PMCID: PMC10707641 DOI: 10.1371/journal.pone.0295167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 11/16/2023] [Indexed: 12/18/2023] Open
Abstract
The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21-28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21-28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.
Collapse
Affiliation(s)
- Burenjargal Batmunkh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Dashpagma Otgonbayar
- National Center for Communicable Diseases of Mongolia, Ulaanbata, Mongolia
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Shatar Shaarii
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Nansalmaa Khaidav
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Oyu-Erdene Shagdarsuren
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gantuya Boldbaatar
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Nandin-Erdene Danzan
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | - Tsolmon Unurjargal
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ichinnorov Dashtseren
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | | | | | - Baasanjargal Biziya
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Seesregdorj Surenjid
- International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Khongorzul Togoo
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ariunzaya Bat-Erdene
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Zolmunkh Narmandakh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gansukh Choijilsuren
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ulziisaikhan Batmunkh
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Chimidtseren Soodoi
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Enkh-Amar Boldbaatar
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Ganbaatar Byambatsogt
- School of Nursing, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Otgonjargal Byambaa
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Zolzaya Deleg
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gerelmaa Enebish
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Bazardari Chuluunbaatar
- Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Gereltsetseg Zulmunkh
- Mongolia-Japan Hospital, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | | | - Batbaatar Gunchin
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Battogtokh Chimeddorj
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Davaalkham Dambadarjaa
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| | - Tsogtsaikhan Sandag
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia
| |
Collapse
|
4
|
Asmar I, Almahmoud O, Yaseen K, Jamal J, Omar A, Naseef H, Hasan S. Assessment of immunoglobin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine. CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH 2023; 22:101330. [PMID: 37293133 PMCID: PMC10239151 DOI: 10.1016/j.cegh.2023.101330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 05/13/2023] [Accepted: 05/25/2023] [Indexed: 06/10/2023] Open
Abstract
Introduction Many countries have begun immunization programs and established protocols to combat pandemics caused by the SARS-CoV-2 virus. Six months after vaccination, the antibody titers produced by the immunization begin to decline, and individuals whose first immunization (either one or two doses) did not provide adequate protection may require a booster dose. Methods A quantitative cross-sectional survey of 18-year-olds and older was undertaken in the West Bank from June 15 to June 27, 2022. Each participant had 5 mL of blood drawn to be tested for IgG-S, IgG-N, and blood group. Results All participants had positive IgG-S results; IgG-S values ranged between 77 and 40,000 AU/ml, with a mean value of 1254 AU/ml. The value of IgG-N ranged from 0 to 139.3 U/ml for all participants, with a mean value of 22.4 U/ml. 64 (37.2%) of the participants demonstrated positive IgG-N screening results, with mean values of 51.2 U/ml. Female participants' mean IgG concentration was higher than male participants. Furthermore, the results revealed that smokers had lower levels of vaccine-induced antibodies than nonsmokers. High significance was found in the time from the last vaccine till the blood sample test (T = 3.848, P < .001), and the group between 6 and 9 months was found to have higher mean values than the 9-months group (M = 15952). Conclusions Participants vaccinated with a higher number of vaccines tend to have higher IgG-S. To elevate total antibodies, booster doses are essential. Additional researchers are needed to examine the positive correlation between IgG-S and IgG-N.
Collapse
Affiliation(s)
- Imad Asmar
- Birzeit University, Palestine
- Department of Nursing, P. O. Box Birzeit 14, Palestine
| | - Omar Almahmoud
- Birzeit University, Palestine
- Department of Nursing, P. O. Box Birzeit 14, Palestine
| | - Khalid Yaseen
- Birzeit University, Palestine
- Department of Nursing, P. O. Box Birzeit 14, Palestine
| | - Jehad Jamal
- Birzeit University, Palestine
- Department of Nursing, P. O. Box Birzeit 14, Palestine
| | - Ahmad Omar
- Birzeit University, Palestine
- Department of Nursing, P. O. Box Birzeit 14, Palestine
| | - Hani Naseef
- Birzeit University, Palestine
- Pharmacy Department, P. O. Box Birzeit 14, Palestine
| | - Shadi Hasan
- Birzeit University, Palestine
- Master program in Clinical Laboratory Science, P. O. Box Birzeit 14, Palestine
| |
Collapse
|
5
|
Eliçabe RJ, Distel MN, Jofré BL, Leporati M, Silva JE, Arias JL, Gorlino CV, Funes SC, Velazquez M, Vitale P, Davicino RC, Di Genaro MS. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. Vaccine 2023; 41:476-485. [PMID: 36481109 PMCID: PMC9676178 DOI: 10.1016/j.vaccine.2022.11.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 11/02/2022] [Accepted: 11/13/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND Although there has developed an increased interest in the vaccines BNT1622b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/NIAID), and ChAdOx1 nCoV-19 (AstraZeneca/University of Oxford), there are still few reports describing the immune response induced by different vaccine platforms in real-world settings of low-income countries. Here, we proposed to analyse the humoral immune response elicited by the primary vaccines used in Argentina from July-December 2021. METHODS Anti-SARS-CoV-2-Spike-RBD IgG and neutralising antibodies were assayed by ELISA in a total of 871 serum samples obtained from 376 volunteers from an educational staff. The individuals were vaccinated with BBIBP-CorV (Sinopharm), ChAdOx1 nCoV-19 (AstraZeneca/University of Oxford, AZ), Gam-COVID-Vac (Sputnik V, SpV) or combined vaccines (mostly SpV and mRNA-1273, Moderna). The antibody response was analysed several days after the initial vaccination (20, 40, 120 and 180 days). RESULTS After receiving at least one dose of the COVID-19 vaccine, we detected 93.34% of seroprevalence. Previously SARS-CoV-2 infected showed higher antibody concentrations compared with naïve vaccinees. Six months after the initial vaccination, combined vaccination induced higher anti-SARS-CoV-2 antibody levels than the other vaccines in naïve volunteers. However, we did not find differences in the neutralising responses after any vaccine from naïve vaccines or between the naïve and previously infected volunteers on day 120 after vaccination. CONCLUSIONS Our long-term analysis of volunteers from the educational system provides data in a real-world context, showing the benefits of a boost dose still in previously infected volunteers, and suggesting the advantages of a heterologous prime-boost schedule.
Collapse
Affiliation(s)
- Ricardo Javier Eliçabe
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Matías Nicolás Distel
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Brenda Lucila Jofré
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Marianela Leporati
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Juan Eduardo Silva
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - José Luis Arias
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Carolina Virginia Gorlino
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Samanta Celeste Funes
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Marisol Velazquez
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - Patricia Vitale
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Centro Oncológico Integral, Hospital San Luis, Avenida del Fundador, 5700 San Luis, Argentina
| | - Roberto Carlos Davicino
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina
| | - María Silvia Di Genaro
- Laboratorio Inmunopatología y Citometría de Flujo, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina,Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), CONICET-UNSL, Ejército de los Andes 950, 5700 San Luis, Argentina,Corresponding author at: Laboratorio de Inmunopatología, Universidad Nacional de San Luis, Ejército de los Andes 950, 5700 San Luis, Argentina
| |
Collapse
|
6
|
Decarreaux D, Sevila J, Masse S, Capai L, Fourié T, Villarroel PMS, Amroun A, Nurtop E, Vareille M, Blanchon T, de Lamballerie X, Charrel R, Falchi A. Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:15257. [PMID: 36429974 PMCID: PMC9691066 DOI: 10.3390/ijerph192215257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 11/10/2022] [Accepted: 11/14/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). AIM This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. METHODS A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. RESULTS Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%). CONCLUSION These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
Collapse
Affiliation(s)
- Dorine Decarreaux
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
- INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Julie Sevila
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Shirley Masse
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Lisandru Capai
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Toscane Fourié
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Paola Mariela Saba Villarroel
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Abdennour Amroun
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Elif Nurtop
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Matthieu Vareille
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| | - Thierry Blanchon
- INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, IPLESP, 75012 Paris, France
| | - Xavier de Lamballerie
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Remi Charrel
- Unité des Virus émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
| | - Alessandra Falchi
- Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France
| |
Collapse
|
7
|
Moghnieh R, El Hajj C, Abdallah D, Jbeily N, Bizri AR, Sayegh MH. Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. Vaccines (Basel) 2022; 10:1596. [PMID: 36298460 PMCID: PMC9607825 DOI: 10.3390/vaccines10101596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/12/2022] [Accepted: 09/16/2022] [Indexed: 11/22/2022] Open
Abstract
In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effectiveness of BNT162b2 after two doses (81%) compared to two doses of Gam-COVID-Vac (41.8%) against the Delta variant of SARS-CoV-2, which correlated with anti-spike antibody levels. Regarding the Omicron variant, protection against infection and antibody levels were severely compromised and the correlation between an anti-spike IgG titer and effectiveness was lost, unlike the situation during the Delta wave. Considering the booster vaccination schemes, a homologous BNT162b2 booster after a BNT162b2 primary vaccination induced a higher humoral immune response when compared to that induced by a heterologous BNT162b2 booster after a Gam-COVID-Vac primary vaccination. However, the VE of both booster regimens against the Omicron variant was almost equal (64% in the homologous regimen and 57% in heterologous regimen). Hybrid immunity evidenced a better humoral response and a greater and longer protection against Delta and Omicron infections compared to vaccination-induced immunity in COVID-19-naïve individuals. Finally, the findings show that VE waned with time during the same wave, highlighting the importance of reinforcing primary and booster COVID-19 vaccination mainly at the beginning of each wave during the surge of a new variant of concern.
Collapse
Affiliation(s)
- Rima Moghnieh
- Division of Infectious Diseases, Department of Internal Medicine, Makassed General Hospital, Beirut P.O. Box 11-6301, Lebanon
- Faculty of Medicine, Lebanese University, Beirut P.O. Box 6573/14, Lebanon
| | - Claude El Hajj
- Faculty of Medicine, Lebanese University, Beirut P.O. Box 6573/14, Lebanon
- Middle East Airlines-AIRLIBAN S.A.L., Beirut P.O. Box 206, Lebanon
| | - Dania Abdallah
- Pharmacy Department, Makassed General Hospital, Beirut P.O. Box 11-6301, Lebanon
| | - Nayla Jbeily
- FMPS Holding S.A.L., Beirut P.O. Box 60 247, Lebanon
| | - Abdul Rahman Bizri
- Department of Internal Medicine, Division of Infectious Diseases, American University of Beirut Medical Center, Beirut P.O. Box 11-0236, Lebanon
| | - Mohamed H. Sayegh
- GAP Solutions under Contract No. 75N93019D00026 with National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, United States of America, Washington, DC 20201, USA
- Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon
| |
Collapse
|
8
|
Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients. Aging (Albany NY) 2022; 14:7193-7205. [PMID: 36152043 PMCID: PMC9550251 DOI: 10.18632/aging.204299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Accepted: 09/05/2022] [Indexed: 11/25/2022]
Abstract
The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70-96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70-74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19.
Collapse
|
9
|
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests. Viruses 2022; 14:v14092041. [PMID: 36146847 PMCID: PMC9502088 DOI: 10.3390/v14092041] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 09/09/2022] [Accepted: 09/12/2022] [Indexed: 11/17/2022] Open
Abstract
The emergence of the new coronavirus SARS-CoV-2 in late 2019 led to the global pandemic COVID-19, causing a profound socioeconomic crisis. Adequate diagnostic tools need to be developed to control the ongoing spread of infection. Virus-specific humoral immunity in COVID-19 patients and those vaccinated with specific vaccines has been characterized in numerous studies, mainly using Spike protein-based serology tests. However, Spike protein and specifically its receptor-binding domain (RBD) are mutation-prone, suggesting the reduced sensitivity of the validated serology tests in detecting antibodies raised to variants of concern (VOC). The viral nucleocapsid (N) protein is more conserved compared to Spike, but little is known about cross-reactivity of the N-specific antibodies between the ancestral B.1 virus and different VOCs. Here, we generated recombinant N phosphoproteins from different SARS-CoV-2 strains and analyzed the magnitude of N-specific antibodies in COVID-19 convalescent sera using an in-house N-based ELISA test system. We found a strong positive correlation in the magnitude of anti-N (B.1) antibodies and antibodies specific to various VOCs in COVID-19-recovered patients, suggesting that the N-binding antibodies are highly cross-reactive, and the most immunogenic epitopes within this protein are not under selective pressure. Overall, our study suggests that the RBD-based serology tests should be timely updated to reflect the constantly evolving nature of the SARS-CoV-2 Spike protein, whereas the validated N-based test systems can be used for the analysis of sera from COVID-19 patients regardless of the strain that caused the infection.
Collapse
|
10
|
Gentile A, Castellano VE, Pacchiotti A, Weinberger N, Diana Menéndez S, Del Pino M, Carciofi G, Lamy P, Mistchenko AS. Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina. Vaccine X 2022; 11:100187. [PMID: 35755140 PMCID: PMC9213035 DOI: 10.1016/j.jvacx.2022.100187] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 06/07/2022] [Accepted: 06/08/2022] [Indexed: 01/06/2023] Open
Abstract
After completing a two-dose Sputnik V schedule, all vaccinees developed antibodies. Prior infection was associated with higher antibody concentrations. Antibodies decreased significantly after 6 months in naïve subjects. In subjects without infection, 17% were negative at day 180. SARS-CoV2 infection after vaccination increased antibody concentrations.
Background In December 2020, Sputnik V was incorporated to the National COVID-19 Immunization Plan in Argentina. Studies had shown 98% of antibody response rate. To date, data on immunogenicity and antibody persistence in Argentina are scarce. The objective was to assess humoral immune response after two doses of Sputnik V in Health Care Workers (HCWs) at the Ricardo Gutierrez Children’s Hospital (RGCH). Methods A prospective, cohort study in HCWs immunized with two doses of Sputnik V between February and March 2021. The following variables were assessed: age, gender, risk factors for severe COVID-19 or mortality, immunosuppressive therapy and history of SARS-CoV-2. Blood samples were drawn on the day of the first dose, 28 days and 180 days after the second. Anti-Spike IgG was measured using an ELISA assay. Differences in immune response were evaluated according to study variables. Comparison analyses between groups with or without history of infection were performed, with T-test and ANOVA or Mann-Whitney tests. For each subject, we compared baseline values with 28 days and 180 days after the second vaccine. STATA version 14 and R Sofware were used for data analyses. Results We included 528 individuals, mean age 41.5 years, 82.9% female, 14.4% (76/528) reported previous SARS-CoV-2 infection. All subjects developed antibodies post-vaccination. At day 28, concentrations were significantly higher in previously infected than naïve subjects (p < 0.001) with no differences according to age, gender and comorbidities. At day 180, 17% (95% CI 13.17–21.53) of naïve subjects were negative. Antibody concentrations decreased significantly in all subjects except in those who reported SARS-CoV-2 infection after vaccination (n = 31). This last group had significantly higher antibody concentrations. Conclusion This study assessed immune response to a new COVID-19 vaccine in real life in a cohort of subjects. Antibody concentrations varied according to history of SARS-COV-2 infection and decreased over time.
Collapse
Affiliation(s)
- A Gentile
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - V E Castellano
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - A Pacchiotti
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - N Weinberger
- Department of Virology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - S Diana Menéndez
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - M Del Pino
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - G Carciofi
- Department of Virology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - P Lamy
- Epidemiology, Ricardo Gutierrez Children's Hospital, Gallo 1330, Buenos Aires City, Argentina
| | - A S Mistchenko
- Commission of Scientific Investigations of the Province of Buenos Aires, Calle 526, La Plata, Buenos Aires Province, Argentina
| |
Collapse
|
11
|
Yegorov S, Kadyrova I, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S, Korshukov I, Baiken Y, Matkarimov B, Miller MS, Hortelano GH, Babenko D. Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. Sci Rep 2022; 12:13207. [PMID: 35915123 PMCID: PMC9342835 DOI: 10.1038/s41598-022-17514-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Accepted: 07/26/2022] [Indexed: 12/30/2022] Open
Abstract
Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID-19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine's effects on systemic immunology.
Collapse
Affiliation(s)
- Sergey Yegorov
- Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
- School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan.
| | - Irina Kadyrova
- Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.
| | - Baurzhan Negmetzhanov
- School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
- National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan
| | | | | | - Ilya Korshukov
- Research Centre, Karaganda Medical University, Karaganda, Kazakhstan
| | - Yeldar Baiken
- School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
- National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan
- School of Engineering and Digital Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan
| | - Bakhyt Matkarimov
- National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan
| | - Matthew S Miller
- Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada
| | - Gonzalo H Hortelano
- School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
| | - Dmitriy Babenko
- Research Centre, Karaganda Medical University, Karaganda, Kazakhstan
| |
Collapse
|
12
|
Ivashkin V, Ismailova A, Dmitrieva K, Maslennikov R, Zharkova M, Aliev S, Bakhitov V, Marcinkevich V. Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. World J Hepatol 2022; 14:1470-1479. [PMID: 36158923 PMCID: PMC9376781 DOI: 10.4254/wjh.v14.i7.1470] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 04/19/2022] [Accepted: 06/16/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The clinical efficacy and safety of vaccination against novel coronavirus disease 2019 (COVID-19) in patients with cirrhosis have not been evaluated yet.
AIM To evaluate the clinical efficacy and safety of vaccination against COVID-19 in patients with cirrhosis.
METHODS This was a retrospective cohort study of patients with cirrhosis. The first cohort included patients vaccinated with Gam-COVID-Vac (Sputnik V); the second one consisted of unvaccinated controls.
RESULTS The study included 89 vaccinated patients and 148 unvaccinated ones. There were 4 cases of COVID-19 in the vaccinated group and 24 cases in the unvaccinated group (P = 0.035). No severe cases of COVID-19 were revealed in the vaccinated group, while there were 12 ones in the unvaccinated group (P = 0.012) with 10 deaths detected (P = 0.012). The vaccine efficacy was 69.5% (95% confidence interval [CI]: 18.5%-94.4%) against symptomatic cases of COVID-19, 100% (95%CI: 25.1%-100.0%) against severe cases, and 100% (95%CI: 1.6%-100.0%) against death associated with COVID-19. The efficacy of full vaccination with revaccination against symptomatic cases of COVID-19 was 88.3% (95%CI: 48.0%-99.6%). The overall mortality rate was higher in the unvaccinated group than in the vaccinated group (17.1% vs 3.0%; P = 0.001). Higher Child-Turcotte-Pugh class cirrhosis (hazard ratio [HR] = 4.13, 95%CI: 1.82-9.35) and higher age (HR = 1.08, 95%CI: 1.04-1.15) were independent predictors of overall mortality, while vaccination had a protective effect (HR = 0.09, 95%CI: 0.01-0.76). There was no significant difference in liver-related mortality (P = 0.135) or the incidence of liver decompensation (P = 0.077), bleeding esophageal varices (P = 0.397), and vascular events (P = 0.651) between the two groups of patients.
CONCLUSION Vaccination against COVID-19 in patients with cirrhosis is effective and safe.
Collapse
Affiliation(s)
- Vladimir Ivashkin
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
| | - Albina Ismailova
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
| | - Ksenia Dmitrieva
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
- Department of Internal Diseases, Consultative and Diagnostic Center № 2 of Department of Health, Moscow 107764, Russia
| | - Roman Maslennikov
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
- Department of Internal Diseases, Consultative and Diagnostic Center № 2 of Department of Health, Moscow 107764, Russia
| | - Maria Zharkova
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
| | - Salekh Aliev
- Administration, Consultative and Diagnostic Center № 2 of Department of Health, Moscow 107764, Russia
- The First Hospital Surgery Department, Pirogov Russian National Research Medical University, Moscow 117997, Russia
| | - Vyacheslav Bakhitov
- Administration, Consultative and Diagnostic Center № 2 of Department of Health, Moscow 107764, Russia
| | - Vadim Marcinkevich
- Administration, Consultative and Diagnostic Center № 2 of Department of Health, Moscow 107764, Russia
| |
Collapse
|
13
|
Benedetti P, Barbuzza A, Moscato F, Reppucci V, Goyeneche C, Katche C, Medina JH, Viola H, Ballarini F, Moncada D. Second Wave of COVID-19 Pandemic in Argentinian Population: Vaccination Is Associated With a Decrease in Depressive Symptoms. Front Psychiatry 2022; 13:832352. [PMID: 35815024 PMCID: PMC9259890 DOI: 10.3389/fpsyt.2022.832352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 05/27/2022] [Indexed: 11/13/2022] Open
Abstract
Background Since the irruption of the coronavirus disease 2019 (COVID-19) the planet has submerged in a time of concern and uncertainty, with a direct impact on people's mental health. Moreover, the recurrent outbreaks that periodically harry different regions of the world constantly refocus people's concerns to the pandemic. Yet, each new wave heats the diverse countries in different situations, including the advances in their vaccination campaigns. In this research, we studied the levels of the general anxiety disorder (GAD) and depression in the Argentine population across the first and second waves of infections that occurred in our country. Methods We conducted an on-line survey, within each peak of the pandemic. People were asked to self-report GAD and depression symptoms using the GAD-7 and PHQ-9 questioners, inform their vaccination status, the frequency they performed physical activity as well as working condition and modality. Here, we identified the more vulnerable groups and evaluated factors that could mitigate the rise of these mental disorders, focusing on vaccination. Results Our data shows that reported GAD and depression levels were higher during the second wave than during the first one. More importantly, vaccinated people were less depressed than non-vaccinated people, while GAD levels remained equivalent in both groups. Other factors directly associated with lower GAD and depression levels were performing frequent physical activity and being employed, regardless of the employment modality. These observations were replicated in different age ranges and genders. Conclusion This work evidences GAD and depression in different pandemic waves in Argentina, as well the factors that may contribute to reducing the magnitude of these disorders, including vaccination.
Collapse
Affiliation(s)
- Pedro Benedetti
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
| | - Alejo Barbuzza
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
| | - Franco Moscato
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
| | | | - Celina Goyeneche
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
| | - Cynthia Katche
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
| | - Jorge H. Medina
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
| | - Haydee Viola
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
- Departamento de Fisiología, Facultad de Ciencias Exactas y Naturales, Biología Molecular y Celular “Dr. Héctor Maldonado” (FBMC), University of Buenos Aires (UBA), Buenos Aires, Argentina
| | - Fabricio Ballarini
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
| | - Diego Moncada
- Instituto Tecnológico de Buenos Aires, Buenos Aires, Argentina
- Facultad de Medicina, Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” (IBCN), UBA-CONICET, Buenos Aires, Argentina
- Centro Integrativo de Biología y Química Aplicada, Universidad Bernardo O'Higgins, Santiago, Chile
| |
Collapse
|
14
|
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines (Basel) 2022; 10:vaccines10050817. [PMID: 35632574 PMCID: PMC9144866 DOI: 10.3390/vaccines10050817] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 05/07/2022] [Accepted: 05/19/2022] [Indexed: 02/01/2023] Open
Abstract
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccinated sera against the Omicron variant are currently being carried out in many laboratories. In this study, we have shown the neutralizing activity of sera against the SARS-CoV-2 Omicron variant compared to the reference Wuhan D614G variant in individuals vaccinated with two doses of Sputnik V up to 6 months after vaccination and in individuals who experienced SARS-CoV-2 infection either before or after vaccination. As a control to our study we also measured neutralizing antibody titers in individuals vaccinated with two doses of BNT162b2. The decrease in NtAb titers to the Omicron variant was 8.1-fold for the group of Sputnik V-vaccinated individuals. When the samples were stratified for the time period after vaccination, a 7.6-fold or 8.8-fold decrease in NtAb titers was noticed after up to 3 and 3-to-6 months after vaccination. We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.
Collapse
|
15
|
Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study. Trop Med Infect Dis 2022; 7:tropicalmed7050066. [PMID: 35622693 PMCID: PMC9145142 DOI: 10.3390/tropicalmed7050066] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 04/06/2022] [Accepted: 04/21/2022] [Indexed: 02/06/2023] Open
Abstract
Insufficient data have been reported about the effect of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) on the humoral response through time in healthcare workers (HCW). This retrospective cohort studied the information of 252 HCW from a private laboratory, comparing the antibody-mediated response provoked by BBIBP-CorV between HCW previously infected with SARS-CoV-2 (PI) and not previously infected (NPI), employing the Elecsys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit at intervals of 21, 90, and 180 days after vaccination. The presence of neutralizing antibodies in HCW 21 days after full vaccination was 100% in PI and 91.60% in NPI. We observed a progressive decrease in antibody levels over time in both groups. Comparing HCW PI with NPI, PI had a 10.9, 14.3, and 8.6-fold higher antibody titer with the Elecsys® anti-SARS-CoV-2 S at 21 (p < 0.001), 90 (p< 0.001) and 180 days (p < 0.001) respectively, compared to NPI. Using the percent of signal inhibition (PSI) of the antibody neutralization cPass™, HCW PI showed a level of 1.3, 2.0, and 3.1 times more antibodies, at 21 (p < 0.001), 90 (p < 0.001), and 180 days (p < 0.001) respectively, compared to NPI. We determined a progressive decrease in humoral immunity over time, particularly higher in those NPI.
Collapse
|